Related Experiment Video
Updated: Jun 9, 2026
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development
Alisa B Lee-Sherick1, Rachel M A Linger, Lia Gore
1Department of Paediatrics, Section of Haematology, Oncology, and Bone Marrow Transplantation, University of Colorado Denver School of Medicine, Aurora, CO, USA.
Insights
New targeted therapies offer hope for children with acute lymphoblastic leukaemia (ALL) who do not respond to standard chemotherapy. These innovative treatments aim to improve cure rates and reduce side effects in high-risk pediatric leukemia patients.
Area of Science:
- Pediatric Oncology
- Hematology
- Cancer Therapeutics
Background:
- Childhood acute lymphoblastic leukemia (ALL) survival has improved significantly due to treatment advancements.
- A notable proportion of pediatric ALL patients experience relapse or refractory disease.
- High-risk patients often require intensified chemotherapy, with limited benefit from minor treatment adjustments.
Purpose of the Study:
- To explore novel targeted therapies for pediatric acute lymphoblastic leukemia (ALL).
- To review targeted agents in clinical trials and preclinical development.
- To highlight potential for improved cure rates and reduced toxicity in ALL treatment.
Main Methods:
- Review of current literature on targeted therapies for childhood ALL.
- Analysis of targeted agents in various developmental stages (clinical trials, research labs).
- Discussion of mechanisms of action and specificity of novel ALL treatments.
Main Results:
- Several novel targeted therapies are under investigation for pediatric ALL.
- These therapies show promise in targeting specific malignant cell phenotypes.
- Potential exists to improve outcomes for relapsed or refractory ALL cases.
Conclusions:
- Targeted therapies represent a promising frontier in treating high-risk childhood ALL.
- These approaches may enhance efficacy while minimizing harm to healthy cells.
- Further research and clinical trials are crucial for advancing ALL treatment.
Abstract:
Modifications to the treatment of acute lymphoblastic leukaemia (ALL) in children have led to a dramatic increase in survival in the past 40 years. Despite this success, a significant subset of paediatric leukaemia patients either relapse or fail to ever achieve a complete remission. Additionally, some patients necessitate treatment with intensified chemotherapy regimens due to clinical or laboratory findings which identify them as high risk. These patients are unlikely to respond to further minor adjustments to the dosing or timing of administration of the same chemotherapy medications. Many novel targeted therapies for the treatment of childhood ALL provide potential mechanisms to further improve cure rates, and provide the possibility of minimizing toxicity to non-malignant cells, given their specificity to malignant cell phenotypes. This article explores many of the potential targeted therapies in varying stages of development, from those currently in clinical trials to those still being refined in the research laboratory.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...